VisualMED Clinical Solutions Corp.
OTC Bulletin Board : VMCS

VisualMED Clinical Solutions Corp.

May 23, 2006 00:54 ET

Dr. Alan Brox to Join VisualMED as Senior Physician

MONTREAL, QUEBEC--(CCNMatthews - May 23, 2006) - VisualMED Clinical Solutions Corp. (the "Company") (OTC BB:VMCS) is pleased to announce that Dr. Alan Brox is joining VisualMED as Senior Physician, effective immediately. Dr. Brox comes to VisualMED following a career in the pharmaceutical industry with Merck Frosst Canada a subsidiary of Merck and Co. where he served as Scientific Director, Oncology and Infectious Disease. Prior to that, he was a Director of Clinical Research at Merck Frosst. His recent responsibilities have focused on the development and execution of clinical trials in oncology and infectious disease, as well as management and training of clinical research personnel.

Dr. Brox received his MD degree from the University of Montreal in 1976, and completed his residency training in Internal Medicine at the Royal Victoria Hospital, part of the McGill University campus. He performed a Fellowship in Hematology-Oncology at the Royal Victoria Hospital and at the Division of Hematology at the University of California at Los Angeles.

Following completion of a post-doctoral fellowship at the McGill Cancer Centre, Dr. Brox joined the Division of Hematology at the Royal Victoria in 1982 where he served as Senior Physician and Associate Professor of Medicine in the Department of Medicine, McGill University. Dr. Brox served as Chief of the Hematology-Oncology Inpatient Service at the hospital for a decade. He presently remains a Senior Physician in the Department of Medicine and is Adjunct Professor in the Department of Oncology at McGill University. He is the author of numerous published papers, articles, and reviews in his field.

Dr. Brox brings more than two decades of clinical and research experience in hematology-oncology to his VisualMED position at a time when VisualMED clinical oncology components are ready for implementation. Dr. Brox will oversee the completion of VisualMED protocol-driven hematology-oncology content as well as the preparation for VisualMED hematology-oncology for implementation in settings where protocol-driven data order and capture is automated in both clinical and clinical-research environments.

"His knowledge in this highly specialized field and his considerable experience in a business setting will help the company to respond to market demand in this critical field," says Chairman Gerard Dab "The company markets its oncology technology as a unique integrated solution for hospitals and stand alone oncology clinics."

About VisualMED oncology

The VisualONCOLOGY framework for ordersets supports the prescription and documentation of any standard or experimental chemotherapeutic protocol. Protocols are loaded into the VisualMED Orderset Administration module by VisualMED staff during implementation of the Clinical Information System. These are updated or modified as necessary by either VisualMED staff or interested individuals on the Oncology Service. No knowledge of computer programming is required to maintain any of the domain content contained in the protocols. The protocols contain not only the chemotherapeutic drug dosages and frequencies, but orders for IV solutions, anti-emetics, scheduled laboratory and image test examinations, blood transfusions, and related nursing activities.

Protocols may be prescribed with one or two keystrokes in many cases; in others, certain patient-specific requirements may be identified and specified during the order entry process. VisualMED decision support is applied at the time a protocol is specified. Dose modifications are recommended by the system in the setting of renal failure, abnormal liver function, and can take into account levels of abnormality of various hematological parameters, as well as patient-specific clinical parameters. The system is able to track lifetime cumulative dose for any medication, and can recommend alternative medications, if indicated, when cumulative doses have been reached. Blood product transfusion can be automatically scheduled based on laboratory results returned on examinations scheduled in the original protocol. Unique to VisualMED, abnormal physical findings or other information recorded in the patient electronic medical record can feed back on individual line items in any protocol. This functionality applies even in the event medical record notations are documented days after the protocol was originally prescribed.

Beginning on the first protocol day, the VisualMED decision-support engine reviews those medications due to be administered on that day to determine if the laboratory, demographic, and clinical conditions which applied at the time the protocol was initiated, remain true. In the event that laboratory or other conditions now exist that did not exist at the time the protocol was initially prescribed, VisualMED notifies the physician through an icon alert system prior to the administration of any medication whose dose or frequency is no longer optimum. The system then recommends alternative dosing according to the requirements in the original protocol. All prescriptions, charting, data collection, and protocol-management is performed in an entirely paperless environment.

About the Company

VisualMED Clinical Solutions Corp. is a leading provider of clinical informatics solutions that help hospitals and healthcare authorities reduce medication errors, increase personnel efficiency and bring down operating costs. One of its key components, a fully integrated Clinical Information System with decision support, is a core solution in the new agenda to promote greater patient safety and reduce the morbidity and mortality associated with medication error. The company is involved in major government initiatives on three continents to modernize hospitals and healthcare delivery.

Detailed information on our company and its products is available on our web site at www.visualmedsolutions.com.

Forward-Looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for the Company's products and services, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

Contact Information